Agios Pharmaceuticals (AGIO) Other Non-Current Liabilities (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 9 years of Other Non-Current Liabilities data on file, last reported at $240000.0 in Q2 2026.

• Quarterly Other Non-Current Liabilities rose 137.62% year-over-year to $240000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $240000.0 (up 137.62% YoY) and the FY2025 annual result came in at $90000.0, down 89.77% from the prior year.
• Other Non-Current Liabilities climbed to $240000.0 in Q2 2026, from $90000.0 in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $3.3 million in Q4 2022 to a low of $90000.0 in Q3 2025.
• A 5-year average of $941705.9 and a median of $1.1 million in 2022 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2025 — Other Non-Current Liabilities slumped 92.21% — and 2026, when it surged 137.62%.
• Tracing AGIO's Other Non-Current Liabilities over 5 years: stood at $3.3 million in 2022, then sank by 64.75% to $1.2 million in 2023, then slipped by 23.88% to $880000.0 in 2024, then plunged by 89.77% to $90000.0 in 2025, then surged by 166.67% to $240000.0 in 2026.
• The last three Other Non-Current Liabilities figures came in at $240000.0 (Q2 2026), $90000.0 (Q1 2026), and $90000.0 (Q4 2025), per Business Quant data.